Volume 13 Supplement 1

Melanoma Bridge 2014: meeting abstracts

Open Access

Exome sequencing in primary melanoma identifies novel drivers of melanoma progression

  • Valentina Montagnani1,
  • Matteo Benelli2,
  • Alessandro Apollo1,
  • Silvia Pandolfi1,
  • Gianni Gerlini3,
  • Lorenzo Borgognoni3 and
  • Barbara Stecca1
Journal of Translational Medicine201513(Suppl 1):P2

https://doi.org/10.1186/1479-5876-13-S1-P2

Published: 15 January 2015

Background

Melanoma is the most aggressive skin cancer due to its high metastatic propensity and resistance to most traditional chemotherapeutic drugs [1, 2]. At early stage melanoma can be cured by surgical excision, whereas metastatic melanoma is a highly lethal condition. To understand melanoma progression is crucial identify mutations that are involved in making an individual melanoma competent for metastatic spread. The most frequent known oncogenic mutation in melanoma is BRAF-V600E and several whole exome sequencing studies have revealed numerous other alterations [36]. It is well established that the aggressive behavior of melanoma is highly correlated with histological features, such as the thickness of the primary tumor and the mitotic index. Here we performed whole exome sequencing of 5 thin (<1mm in thickness) and 5 thick (>4mm in thickness) primary melanomas compared to matched-normal DNA.

Materials and methods

We have collected 10 fresh primary melanomas from 10 untreated patients: DNA samples from melanoma tissues and peripheral blood (normal DNA) were available from all of the recruited patients. Genomic DNA was extracted from tumor and peripheral blood samples using the QIAamp DNA Minikit, (Qiagen, Hilden, Germany). Extracted DNA was used for Next-Generation Sequencing analysis by Illumina.

Results

We confirmed recurrent somatic mutations in known melanoma-related genes, including BRAF, c-KIT, EGFR, PPP6C, MLL3 and several components of the glutamate signaling. In addition, we discovered mutations in genes not previously linked to this tumor, such as CSMD1, FGFR4 and components of the Hedgehog (HH) signaling pathway. In particular, in a thick melanoma we found a novel activating mutation in the transcription factor GLI1, one of the final effectors of the HH signaling. Additionally, we identified candidate metastasis-driving mutations such as ADAMTS6, ADAMTS7, CHD9, MLL3, NALCN and TSC2 in the 3 thick melanomas that produced metastasis. Interestingly, we identified several regions of focal somatic copy-number alterations (SCNAs) that were altered at significantly higher frequency in thick compared to thin melanomas. Several gene families are comprised among these regions of focal SCNAs, including components of Notch, HH and Wnt/β-catenin signaling pathways, BRAF, c-MYC and its cofactor PIM1, several ADAMs, EGFR and the HOX genes.

Conclusion

Our data identify potential drivers of melanoma progression, enhancing our understanding of the genomic complexity underlying melanoma.

Authors’ Affiliations

(1)
Laboratory of Tumor Cell Biology, Core Research Laboratory, Istituto Toscano Tumori
(2)
Diagnostic Genetic Unit, Laboratory Department, Careggi University Hospital
(3)
Plastic Surgery Unit, S.M. Annunziata Hospital - Regional Melanoma Referral Center, Istituto Toscano Tumori

References

  1. Chudnovsky Y, Khavari PA, Adams AE: Melanoma genetics and the development of rational therapeutics. J Clin Invest. 2005, 115 (4): 813-824. 10.1172/JCI24808.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Walia V, Mu EW, Lin JC, Samuels Y: Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res. 2012, 25 (2): 155-170. 10.1111/j.1755-148X.2012.00976.x.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Wei X1, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, NISC Comparative Sequencing Program, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y: Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011, 43 (5): 442-446. 10.1038/ng.810.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, Michielin O, Muehlethaler K, Speiser D, Beckmann JS, Xenarios I, Halazonetis TD, Jongeneel CV, Stevenson BJ, Antonarakis SE: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 2011, 44 (2): 133-139. 10.1038/ng.1026.View ArticlePubMedGoogle Scholar
  5. Stark MS, Woods SL, Gartside MG, Bonazzi VF, Dutton-Regester K, Aoude LG, Chow D, Sereduk C, Niemi NM, Tang N, Ellis JJ, Reid J, Zismann V, Tyagi S, Muzny D, Newsham I, Wu Y, Palmer JM, Pollak T, Youngkin D, Brooks BR, Lanagan C, Schmidt CW, Kobe B, MacKeigan JP, Yin H, Brown KM, Gibbs R, Trent J, Hayward NK: Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet. 2011, 44 (2): 165-169. 10.1038/ng.1041.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012, 44 (9): 1006-1014. 10.1038/ng.2359.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Montagnani et al; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement